Roth starts BioBlast Pharma at buy
Roth Capital Partners has initiated coverage of BioBlast Pharma (NASDAQ:ORPN) with a “buy” rating and $15 price target. The stock closed at $7.68 on Friday. BioBlast has three proprietary platform...
View ArticleRoth ups BioBlast Pharma target price to $25
Roth Capital Partners has raised its price target for BioBlast Pharma (NASDAQ:ORPN) to $25 from $18 after the company announced plans to initiate a placebo-controlled, multi-center Phase 3 study for...
View ArticleRodman starts BioBlast Pharma at buy
Rodman & Renshaw has initiated coverage of BioBlast Pharma (NASDAQ:ORPN) with a “buy” rating and 12-month price target of $25. The stock closed at $3.24 on Wednesday. BioBlast is focused on...
View Article
More Pages to Explore .....